Approval · Notice of Compliance 7218 · 2005
ABREVA: Notice of Compliance 7218
Issued July 6, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7218
- Date
- July 6, 2005
- Company
- Glaxosmithkline Consumer Healthcare UlcMississauga, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Product name change
- Therapeutic class
- Viral entry blocking agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABREVA | 02245677 | — |
Medicinal ingredients
- DOCOSANOL 10 PER